Not Signed In -
Rasburicase |
Elitek |
Rasburicase Systematic (IUPAC) name Aspergillus urate oxidase Identifiers CAS number 134774-45-1 ATC code V03AF07 PubChem ? DrugBank BIOD00090 Chemical data Formula C1521H2381N417O461S7 Mol. weight 34109.5 Pharmacokinetic data Bioavailability N/A Metabolism ? Half life 8 hrs Excretion ? Therapeutic considerations Pregnancy cat. ? Legal status RX/POM Routes Intravenous Rasburicase (brand names: Fasturtec and Elitek) is a re ...
Wikipedia - [full article]
Rasburicase Clinical Trials
- Rasburicase in Treating or Preventing High Levels of Uric Acid in the Blood and Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumors
ClinicalTrials.gov Identifier: NCT00086918 - Active, not recruiting
Cancer; hyperuricemia; Tumor Lysis Syndrome
- Rasburicase in Tumor Lysis Syndrome
ClinicalTrials.gov Identifier: NCT00302653 - Active, not recruiting
Hyperuricemia
- Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
ClinicalTrials.gov Identifier: NCT00186940 - Recruiting
Leukemia; Lymphoma
- Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
ClinicalTrials.gov Identifier: NCT00057811 - Recruiting
acute leukemia; childhood large cell lymphoma; childhood small noncleaved cell lymphoma; Drug Toxicity
- Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
ClinicalTrials.gov Identifier: NCT00230217 - Active, not recruiting
Tumors; Hyperuricemia; Tumor Lysis Syndrome
- Study of Rasburicase Versus Allopurinol in Patients With Leukemia, Lymphoma, or Solid Tumor Malignancy at Risk for Hyperuricemia and Tumor Lysis Syndrome
ClinicalTrials.gov Identifier: NCT00230178 - Active, not recruiting
Tumor Lysis Syndrome; Cancer; Hyperuricemia
- Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma
ClinicalTrials.gov Identifier: NCT00199043 - Recruiting
Adult Acute Lymphocytic Leukemia; High-Grade Lymphoma
- Rasburicase for Hyperuricemia
ClinicalTrials.gov Identifier: NCT00290992 - Completed
Nutritional and Metabolic Diseases
- Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
ClinicalTrials.gov Identifier: NCT00513474 - Not yet recruiting
Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
- Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome
ClinicalTrials.gov Identifier: NCT00563771 - Completed
Hyperuricemia
- Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
ClinicalTrials.gov Identifier: NCT00360438 - Completed
Leukemia; Lymphoma; Tumor Lysis Syndrome
Resources
- Elitek (Drug Digest)
- Rasburicase (Drug Digest)
email this page
print this page
bookmark this page
feedback on this page
